The Effects of Atorvastatin Treatment in COPD Patients
Study Details
Study Description
Brief Summary
Rationale: Retrospective studies suggest that statins improve outcomes in COPD patients possibly as a result of an anti-inflammatory effect.
Objectives: To determine whether statins have an anti-inflammatory effect on the lungs of patients with COPD.
A controlled, parallel group study to compare the effects of Atorvastatin in comparison to placebo as an add-on treatment to Formoterol therapy in patients with mild to moderate COPD in group of 20 patients. All subjects will have spirometry, lung volumes, DLCO, SGRQ, 6MWD, serum lipids and hs-CRP measured before and after treatment. Bronchoscopy and transbronchial lung biopsy (TBB) will be carried out at baseline and after 12 weeks of treatment, and TBB specimens will be processed for histology, immunohistochemistry and microarray analysis.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 4 |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Active Comparator: Atorvastatin 40 mg of Atorvastatin once daily as add-on to Formoterol only 12 weeks therapy. |
Drug: Atorvastatin
Other Names:
Drug: Formoterol
12mcg of Foradil BID as maintenance COPD treatment in both treatment arms
Other Names:
|
| Placebo Comparator: Lactose tablet One tablet taken once a day as add-on treatment to Formoterol baseline 12 weeks therapy. |
Drug: Formoterol
12mcg of Foradil BID as maintenance COPD treatment in both treatment arms
Other Names:
Drug: Lactose tablet
One lactose tablet taken once a day as add-on treatment to Formoterol therapy
|
Outcome Measures
Primary Outcome Measures
- Change in CD45+ cells expression over study period [12 weeks]
Change in CD45+ cells expression measured by immunohistochemistry in lung biopsy samples assessed before and after 12 weeks of treatment
- Change in gene expression over study period [12 weeks]
Change in gene expression measured in lung biopsy samples measured using microarrays before and after 12 weeks of treatment
Secondary Outcome Measures
- Change in health related quality of life over study period [12 weeks]
Change in health related quality of life assessed by St. George's respiratory questionnaire before and after 12 weeks of treatment
- Change in 6-Minute Walk Distance over study period [12 weeks]
Change in 6-Minute Walk Distance measured according to 6-MWD protocol before and after 12 weeks of treatment
- Change in intimal-medial thickness over study period [12 weeks]
Change in intimal-medial thickness (IMT) measured in the common carotid artery (CCA) using a standard technique.
- Change in hs-CRP over study period [12 weeks]
Change in serum hs-C-reactive protein (hs-CRP) measured before and after 12 weeks of therapy
- Change in total cholesterol, LDL and HDL-Cholesterol and triglycerides over study period [12 weeks]
Change in total cholesterol, LDL and HDL-Cholesterol, and triglycerides measured before an after 12 weeks of therapy.
Other Outcome Measures
- Change in lung volumes over study period [12 weeks]
Change in lung volumes measured using body plethysmography before and after 12 weeks of treatment
- Change in FEV1 over study period [12 weeks]
Change in FEV1 measured using spirometry before and after 12 weeks of treatment
Eligibility Criteria
Criteria
Inclusion Criteria:
. Written informed consent must be obtained before any assessment is performed. 2. Male and female adults aged ≥40 years, who have signed an Informed Consent Form prior to initiation of any study-related procedure.
-
Patients with moderate to very severe stable COPD (Stage II-IV) according to the GOLD guidelines.
-
Patients with a post-bronchodilator FEV1 < 80% of the predicted normal, and a post-bronchodilator FEV1/FVC < 0.70 at Visit 1.
-
Current or ex-smokers who have a smoking history of at least 10 pack years
Exclusion criteria
-
Pregnant or nursing (lactating) women
-
Women of child-bearing potential, unless they are using effective methods of contraception during dosing of study treatment. 5. 3. Patients with a clinically significant abnormality at Visit 1.
-
Patients with a clinically relevant laboratory abnormality at Visit 1 5. Patients with a history of malignancy of any organ system (including lung cancer).
-
Patients contraindicated for treatment with statins 7. Patients unable to perform acceptable spirometry and lung volumes procedures.
-
Patients who have had a COPD exacerbation that required treatment with antibiotics and/or oral corticosteroids and/or hospitalization in the 6 weeks prior to Visit 1.
-
Patients who have had a respiratory tract infection within 4 weeks prior to Visit 1.
-
Patients requiring oxygen therapy (>15 hr/day) on a daily basis for chronic hypoxemia
-
Patients with any history of asthma or onset of symptoms prior to age 40 years.
-
Patients with concomitant pulmonary disease, (e.g. lung fibrosis, sarcoidosis, interstitial lung disease, pulmonary hypertension, tuberculosis).
-
Patients with primary bronchiectasis. 14. Patients with a diagnosis of α-1 anti-trypsin deficiency. 15. Patients with pulmonary lobectomy or lung volume reduction surgery or lung transplantation.
-
Patients participating in or planning to participate in the active phase of a supervised pulmonary rehabilitation program during the study.
-
Patients receiving any medications in the class listed in Table 5.1 18. Use of other investigational drugs within 30 days prior to visit 1.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Department of Lung Diseases and Tuberculosis, Medical University of Bialystok | Bialystok | Poland | 15-540 |
Sponsors and Collaborators
- Medical University of Bialystok
Investigators
- Principal Investigator: Robert M Mroz, MD, Medical University of Bialystok, Bialystok, Poland
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 113-46-966
- N N402 593440